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Summary Salmeterol has earlier been reported to have immune modulating effects
on Lipopolysaccharide (LPS)-induced neutrophilic inflammation in rodents. The aim
of this study was to explore whether 3 weeks regular treatment with inhaled
Salmeterol would have a protective effect against neutrophilia, following an LPS
inhalation as assessed by bronchoscopy with bronchial wash (BW) and bronchoal-
veolar lavage ( BAL ) in healthy subjects. Fifteen volunteers all underwent
bronchoscopies with bronchial wash and BAL on three occasions, each being 3 h
after inhalation provocation. The initial inhalation was with saline (dilutant) as a
reference and the two following with LPS 50 mg diluted in saline. After the saline
inhalation the subjects were randomised to treatment with Salmeterol 50 mg twice
daily and placebo in a double-blind double-dummy crossover design. Compared to
saline inhalation, the LPS inhalations resulted in a two-fold increase in neutrophils
both in BW and BAL, respectively (Pp0.01). The neutrophilia was present
irrespective of the LPS inhalation was preceded by placebo or Salmeterol. This
experimental study could not confirm any modulating effect of Salmeterol on LPS-
induced airway neutrophilia.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Lipopolysaccarid (LPS) endotoxin, is normally found
in the cell walls of Gram-negative bacteria. Apart
from mediating effects during G bacterial infec-
tions, LPS also plays a role for respiratory health
following inhalation of organic dust in cotton mills,
poultry houses, swine confinement buildings, saw-
mills and many other places. Workers in these
enviroments have an increased prevalence of air-
way symptoms, predominantly cough and phlegm1
but wheeze and chest tightness have also been
observed.2,3 Several studies have shown a chronic
airway inflammation as assessed by bronchoalveo-
lar lavage (BAL) with an increased number of
neutrophils in the airways of swine farmers4–6 as
well as in farmers inhaling grain dust.7 In experi-
mental studies in man, inhaled LPS has been found
to induce fever and chills, combined by transient
bronchoconstriction. Bronchial hyperreactivity and
a decrease in carbon monoxide transfer factor have
also been shown.8–10 The local airway effects of
inhaling pure LPS have been evaluated experimen-
tally with bronchoscopy technique in one previous
study. In that study healthy non-smoking subjects
were investigated with bronchoalveolar lavage
(BAL) after inhalation provocation with 100 mg
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prominent airway inflammation with approximately
100-fold increase in neutrophils and a tripling in
number of lymphocytes in BAL fluid.
Salmeterol, an inhaled long-acting b2-agonist has
in several clinical studies been shown to give
excellent asthma control when added to inhaled
corticosteroids. We recently investigated whether
the high degree of asthma control seen with
inhaled salmeterol was only due to its bronchodi-
lating capacity or modulation of asthmatic airway
of inflammation. We demonstrated salmeterol
capable of improving asthma control in parallel
with suppression of the airway inflammatory con-
dition in particular with regard to mast cell
effects.12 A suppressive effect of salmeterol has
been suggested both in animal and in vitro stu-
dies.13–16
In two animal studies, Whelan et al. demon-
strated salmeterol to inhibit LPS-induced neutro-
phil accumulation in guinea pig lung.13,14
Salmeterol has been reported to suppress LPS-
induced cytokine production and to have a protec-
tive effect in a galactosamine/LPS model of
endotoxin shock.15 Furthermore, endothelial per-
meability has been shown to be contracted by
pretreatment of salmeterol in in vitro models.16
The aim of the study was to evaluate whether
regular salmeterol treatment in healthy subjects
would have a protective effect against airway
neutrophilia induced by LPS inhalation. If such an
effect could be confirmed, this would broaden the
base for understanding the capability of salmeterol
to interact with inflammatory airway events.
Additionally, it would give support for a potential
treatment effect in individuals experiencing ad-
verse respiratory effects from inhaled LPS from
organic dust in their work environments.
Methods
Subjects
Fifteen healthy non-smoking volunteers, seven
women, mean age 25 years (range 21–38 years)
with no history of allergy or asthma participated in
the sudy. No upper or lower respiratory infection
was permitted within at least 4 weeks before the
start as well as during the study.
Study design
After a screening visit the volunteers all underwent
inhalations with saline alone, serving as a reference
for subsequent inhalations, when saline was used as
a diluent. After the saline inhalation the subjects
were randomised to treatment with salmeterol
50 mg and placebo twice daily, in a double-blind
double-dummy crossover design. During the end of
each of the 3-week treatment periods an inhalation
with LPS 50 mg diluted in saline was given. The
interval between the inhalation challenges was at
least 3 weeks. Three hours after each of the three
inhalation challenges a bronchoscopy with airway
sampling was performed. The time point was
chosen to reflect an early established LPS-induced
inflammation. The last dose of the 3 weeks
treatment of salmeterol/placebo was given in the
morning 1–2 h before the LPS challenges. The Ethics
Committee of Ume(a University had approved the
study and each subject gave written informed
consent.
LPS-inhalation
LPS-exposure was performed with LPS from Escher-
ichia coli (E.coli serotype 026:B6. prepared using a
phenol extraction procedure, Sigma Chemical. St.
Louis. USA). One mg was suspended in 10ml NaCl to
a dilution of 100 mg/ml. This solution was then
further diluted to a final concentration of 25 mg/ml
and 2ml (50 mg) was inhaled for a period of 10-
15min from a Pari–Boy nebulizer. The dose was
chosen after previous experiments to give a clearly
defined neutrophil inflammation in the bronchi as
described in Sandstr .om. et al.11 In previous experi-
ments using the Pari Boy nebulizer it has been
shown to produce a particle size with a mass
median diameter of 3.5 mm (range 0.5–5.5 mm). The
dose delivered to the lower airways has been
calculated to be approximately 50%.8 The initial
reference inhalation consisted of 2ml of the saline
dilutant alone.
Lung function test
A standard dry bellows spirometer (Vitalograph)
was used throughout the study to measure forced
expiratory volume at 1 s (FEV1). The highest of at
least three measurements was recorded. FEV1 was
measured before inhalation (0 h) and before
bronchoscopy (3 h).
Fiberoptic bronchoscopy
The bronchoscopy premedication consisted of
atropine (0.5–1.0mg) s.c. Lidocaine was used for
topical anaesthesia. The subjects were examined in
supine position using an Olympus BF T10 or BF T20
fiberoptic bronchoscope (Olympus Optical Co.
ARTICLE IN PRESS
1088 A. Wallin et al.
Tokyo. Japan). After wedging the bronchoscope in a
segmental bronchus of the lingula or the middle
lobe a bronchial wash and a BAL were performed.
For the bronchial wash two 20ml aliquots of sterile
phosphate buffered saline was installed and gently
suctioned back followed by the BAL in 3 aliquots of
60ml each. The saline was prewarmed to 371C.
The BAL fluid was kept on ice during the
transport to the laboratory. After filtration through
a nylon filter (pore diameter 100 mm. Syntab
Product AB. Malm .o. Sweden) the fluid was centri-
fuged at 400G for 15min at 41C. The cells were
immediately processed and the supernatant frozen
at 801C. The cells were resuspended in a balanced
salt solution adjusted to pH 7.0 to a concentration
of 106 inflammatory cells/ml. The total number of
cells was counted with a B .urker chamber. Slides for
cytological studies were made using a Cytospin 3R
(Shandon Southern Instruments Inc. Sewickly, PA,
USA) at 1000 rpm for 5min. The non-epithelial cells
on each slide were stained with May–Gr .unwald
Giemsa before differential counting which was
based on at least 400 cells per slide.
Albumin and total protein were analysed at the
Department of Clinical Chemistry at the University
Hospital.
Data analysis
The nonparametric Wilcoxon’s rank sum test was
used to compare changes in BAL and BW parameters
after saline inhalation (baseline), with LPS expo-
sure preceded by salmeterol (LPSþ Salm) or by
placebo treatment (LPSþ Placebo). FEV1 was ana-
lysed with the same statistical method to identify a
potentional decrease in lung function after LPS
inhalation.
A P-valueo0.05 was considered statistically
significant.
Results
Data from the bronchoalvelolar lavage is given in
Table 1. LPS inhalation after treatment with either
salmeterol or placebo resulted in a significant
increase in both the percentage and the total
amount of neutrophils in the bronchial wash and
the BAL compared with the saline inhalation at the
study start. The percentage of neutrophils in-
creased in the bronchial wash from 16.5713.5
after saline to 41.2717.6 after LPSþ Salm,
(Po0.001 vs. saline) and 36.5714.3 after
LPS7Placebo, (Po0.01 vs.saline). In the BAL
similar results was found. The percentage of
neutrophils in BAL increased significantly from
2.871.2 to 9.378.8 after LPSþ Salm, (Po0.01
vs. saline) and to 6.873.8 after LPSþ placebo,
(Po0.01 vs. saline). There was no signficant
differences between pre-treatment with salmeter-
ol and placebo. The increase in neutrophils was
paralleled by a decrease in the percentage of
macrophages. No effects on total cells, lympho-
cytes, albumin or total protein were detected after
LPS inhalation, compared with saline.
The morning FEV1 increased after 3 weeks of
inhaled salmeterol treatment compared with after
placebo, representing a small but significant
bronchodilation in the study population (Table 2).
No decrease in FEV1 was detected after LPS
inhalation.
Discussion
In this study LPS inhalation in healthy volunteers
was demonstrated to induce a significant increase
in airway neutrophils as reflected in both BW and
BAL. This increase was seen irrespectively of
whether three weeks pre-treatment with inhaled
salmeterol 50 mg twice daily or placebo had been
given or not.
The benefit of adding a long-acting b2-agonist
rather than doubling the dose of inhaled corticos-
teroid has been well established in asthma both
when assessing pulmonary function and sym-
toms.17,18 In two recent studies with bronchial
biopsies in asthmatics, salmeterol treatment was
associated with suppressive effects on eosinophils
and mast cells.12,19 We have also demonstrated
similar effects of another long-acting inhaled b2-
agonist, formoterol, on steroid na.ıve asthmatic
subjects.20 Salmeterol has also been shown to have
the capability to reduce neutrophils in the bron-
chial mucosa of mild asthmatic subjects, accom-
panied by suppressed myeloperoxidase and E-
selectin levels in serum.21 The suppressive effects
on asthmatic airway inflammation may represent
links to favourable clinical effects of long-acting b2-
agonists, and the underlying mechanisms mediating
these effects are currently subject for further
studies. The observations, of additional antiinflam-
matory effects on LPS-induced inflammation by
salmeterol treatment in animal and in-vitro mod-
els, triggered the question on whether similar
effects would be present in humans exposed to LPS.
The present study was designed to produce a less
pronounced neutrophil influx after LPS inhalation
compared to our preceding study.11 After pilot
experiments the dose of LPS was decreased to 50 mg
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compared with the previously used 100 mg. In the
present study the neutrophil numbers were
doubled in BW and tripled in BAL after LPS
inhalation compared to after saline inhalation.
Despite this moderate but significant LPS induced
increase in neutrophils salmeterol was not demon-
strated to inhibit this migration of neutrophils. The
differing outcome in the present study in human
volunteers compared to the in vitro and animal
studies can have several explanations.
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Table 1 Bronchoalveolar lavage (BAL) and bronchial wash (BW) components after saline inhalation, and after
LPS inhalation preceded by 3 weeks treatment with inhaled salmeterol or placebo.
After saline inhalation
at study start
After LPSþ saline inhalation,
during salmeterol treatment
After LPSþ saline inhalation,
during placebo treatment
Total cells 109/l
BW 14.3711.3 12.7711.3 15.2714.2
BAL 10.773.1 11.575.4 12.274.4
Neutrophils %
BW 16.5713.5 41.2717.6*** 36.5714.3**
BAL 2.871.2 9.378.8** 6.873.8**
Neutrophils 109/l
BW 1.971.2 4.473.0** 5.676.5***
BAL 0.370.2 1.070.8** 0.970.5**
Lymphocytes %
BW 3.373.0 2.272.0 2.671.8
BAL 12.574.4 10.574.8 14.777.0
Lymphocytes 109/l
BW 0.670.9 0.370.3 0.470.4
BAL 1.470.7 1.371.0 1.971.2
Macrophages %
BW 79.7713.1 56.4717.1*** 60.6714.2**
BAL 84.374.5 80.178.7 78.179.0*
Macrophages 109/l
BW 11.6710.0 7.979.9 9.278.2
BAL 9.072.5 9.374.7 9.473.4
Eosinophils %
BW 0.3370.59 0.2470.39 0.2070.51
BAL 0.3470.54 0.1670.15 0.2970.43
Albumin mg/lw
BW 34.7722.8 28.4719.7 38.6721.5
BAL 48.0732.0 42.4724.1 51.2722.0
Total protein mg/lw
BW 45.7730.9 39.9727.1 51.6733.8
BAL 49.3736.1 45.8730.9 55.0727.4
*Po0.05 **Po0.01 ***Po0.001 compared with saline inhalation.
Data are given as mean7SD. n¼ 15 except windicating n¼ 14.
Table 2 FEV1 at 0 and 3 h after inhalation. Inhalation with saline at start and with LPS diluted in saline after pre
treatment with salmeterol or placebo.
FEV1 (L)
w Before inhalation time 0 h Before bronchoscopy time 3 h
No No
At start Saline (14) 4.2670.96 (10) 3.9070.64
Salm LPSþ Saline (15) 4.4070.86n (15) 4.4170.89
Placebo LPSþ Saline (15) 4.1970.90 (13) 4.3070.88
wValues are expressed as mean7SD.
nP¼ 0.003 salmeterol vs placebo.
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Firstly, there could be species differences and
differing functions in in vitro systems, that could
cause contrasting results.
Secondly, the salmeterol dose. In animal studies,
relatively high doses have been given per kg to
small animals, in contrast to the standard 50 mg
twice daily given to humans.12,13
Thirdly, the effect of a single dose of salmeterol
could differ from repeated doses. In a study by
Giannini et al.22 the protective effect of a single
dose of salmeterol, against allergen induced early
asthmatic reaction (EAR), was lost after regular
treatment with salmeterol for 1 week.
Fourthly, the effect of salmeterol could poten-
tially differ between healthy subjects and those
with allergic asthma and/or rhinitis. Salmeterol has
recently been demonstrated to have the capability
to reduce neutrophils in the bronchial mucosa of
mild asthmatic subjects, which supports the possi-
bility for differentiating effects.21 It could be
speculated that the mechanisms for neutrophil
recruitment could be at least partly different in a
chronic disease as asthma as compared with LPS
challenge. In addition to the suppression of asth-
matic airway inflammation, salmeterol has also
been shown to reduce vascular permeability in
subjects with allergic rhinitis.23
In our previous LPS study an increase in lympho-
cytes was shown in lavage fluid.11 This could not be
seen in the current samples. The reason for this
could be the lower dose of LPS used in the present
study or possibly due to an earlier time point for
the bronchoscopy, 3 h after inhalation. No decrease
in lung function was detected after LPS inhalation.
This is in contrast to some other studies8,10 and
probably reflects the outcome of the lower provo-
cative dose of LPS given. Instead a modest and not
clincially significant increase in FEV1 was detected
after 3 weeks treatment with salmeterol compared
with placebo. This increase in lung function after
salmeterol treatment reflects a minor bronchodila-
tion by the b2-agonist in the investigted non-
asthmatic subjects This isn’t a surprising result
given the subjects are healthy volunteers.
It is concluded that with the present experi-
mental model and study design no protective effect
could be identified by 3 weeks treatment with
inhaled salmeterol 50 mg twice daily, as compared
to placebo, against LPS induced airway inflamma-
tion, in a population of healthy subjects.
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